Business Context and Reporting Period
Company: Ocular Therapeutix, Inc. (OCUL)
Filing Type: Form 8-K (Current Report)
Report Date: August 9, 2021
Reporting Period: Second Quarter ended June 30, 2021
Context: This filing serves to announce the financial results for the quarter ended June 30, 2021. The detailed results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references the announcement of financial results but does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the referenced Exhibit 99.1 (Press Release), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that financial results for the quarter ended June 30, 2021, were announced.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the full text of the press release containing management commentary, outlook, and guidance is furnished as Exhibit 99.1.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt. The filing includes a standard disclaimer that the information is furnished to comply with Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 9, 2021) for specific revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full announcement.
- Confirm if the company provided updated full-year 2021 financial guidance in the press release.